surmount 1 tirzepatide Gastrointestinal tolerability and weight reduction associated with in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 SURMOUNT-1: Tirzepatide Drastically Reduces Weight

Krner, M., Stckli, M., Waser, B

Biological systems tend toward homeostasis, and prolonged interference with any single pathway component may trigger adaptive responses

Abstract Significance: The antiulcer peptide, stable gastric pentadecapeptide BPC 157 (previously employed in ulcerative colitis and multiple sclerosis trials, no reported toxicity (LD1 not achieved)), is reviewed, focusing on the particular skin wound therapy, incisional/excisional wound, deep burns, diabetic ulcers, and alkali burns, which may be generalized to the other tissues healing

Preclinical data suggest good tolerability, but rigorous human safety work is limited

Researchers demonstrated through optogenetic stimulation studies that activation of the GLP-1 receptor in this MHb-IPN circuit eliminates nicotine reward and reduces nicotine intake